Allergan, Inc.

Gilead Sciences, Inc.

Selcia Limited

Rhone Poulenc Agriculture Limited

Cypralis Limited

Simon Neil Pettit

Hans G Fliri

Richard L Mackman

Linos Lazarides

Victoria Alexandra Steadman

Andrew John Keats

Karine G Poullennec

June Chen

Dustin S Siegel

Petr Jansa

Adam James Schrier

Kapil Kumar Karki

Caroline Aciro

David Kenneth Dean

Adrian John Highton

Neil Andrew Dunbar

Michael E Garst

Philip H Smith

Jean Yves Chiva

Andrew D Jones

Catherine Simone V Frydrych

Tibor Musil

Susan Mary Cramp

Todd Appleby

Jonathan Sanvoisin

Gregory M Watt

Alex J Thomas

David Frederick Woodward

William Robert Carling

Jenny W Wang

Paul A Cain

Jose L Martos

Claude Lambert

Richard Henry Hewett

Derek Ian Wallis

John Morris

Gillian Mary Little

Thomas David Yarwood

Clive L Cornell

Philip Henry Gaunt Smith

Dustin Scott Siegel

Andrew J Keats

Victoria A Steadman

Macrocyclic inhibitors of flaviviridae viruses

The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.

Cyclosporins modified on the MeBmt sidechain by heterocyclic rings

The present invention relates to cyclosporin analogs that are potent inhibitors of cyclophilin D and have low immunosuppressive activity; processes for preparing them; pharmaceutical compositions containing them; and methods for using these analogs and compositions containing them for the treatment of medical conditions, including but not limited to ischemic conditions, such as ischemia-reperfusion (I/R) injury, including myocardial FR injury, cerebral I/R injury, and ocular or retinal I/R injury.

Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized

Provided are compounds of Formula I:  and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

The present specification discloses cannabinoid-2 agonists, compositions comprising such cannabinoid-2 agonists, and methods of treating an individual suffering from a disease by administering compositions comprising such cannabinoid-2 agonists.

Cannabinoid-2 agonists

Cyclosporin A analogs

The present specification discloses cannabinoid-2 agonists, compositions comprising such cannabinoid-2 agonists, and methods of treating an individual suffering from a disease by administering compositions comprising such cannabinoid-2 agonists. (Formula I and III) 

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, Rand Rare as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.

Abnormal cannabidiols as agents for lowering intraocular pressure

The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, Rand Rare as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound.

Growing community of inventors

Essex, United Kingdom

Simon Neil Pettit